Meeting
2023 ASCO Annual Meeting
Impact of number and size of colorectal metastases (CRM) on survival in patients with RAS wild-type metastatic colorectal cancer treated within the PanaMa trial (AIO KRK 0212).
Authors
Greta Sommerhäuser
Department of Hematology, Oncology and Tumorimmunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
Greta Sommerhäuser , Annika Kurreck , Alexander Beck , Uli Fehrenbach , Meinolf Karthaus , Stefan Fruehauf , Ullrich Graeven , Lothar Mueller , Alexander Koenig , Ludwig Fischer Von Weikersthal , Johanna Wanda Meyer-Knees , Alexej Ballhausen , Arndt Stahler , Volker Heinemann , Swantje Held , Annabel Helga Sophie Alig , Stefan Kasper , Sebastian Stintzing , Tanja Trarbach , Dominik Paul Modest
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT01991873
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3551)
DOI
10.1200/JCO.2023.41.16_suppl.3551
Abstract #
3551
Poster Bd #
251
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: An analysis of the Panama trial (AIO KRK0212).
First Author: Alexej Ballhausen
Poster
2022 ASCO Annual Meeting
Impact of age and gender on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC): Subgroup analysis of the PANAMA-study (AIO-KRK-0212).
First Author: Kathrin Heinrich
Poster
2022 ASCO Annual Meeting
Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of panitumumab (Pmab), fluorouracil and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab-FOLFOX induction in RAS wildtype metastatic colorectal cancer (mCRC): PANAMA trial (AIO-KRK-0212).
First Author: Beeke Hoppe
Poster
2022 ASCO Annual Meeting
Predictive and prognostic value of carcinoembryonic antigen (CEA) on maintenance therapy with 5-fluoruracil/leucovorin plus panitumumab or 5-fluoruracil/leucovorin alone in RAS wildtype metastatic colorectal cancer: Evaluation of the phase II PanaMa trial (AIO KRK 0212).
First Author: Annika Kurreck